MLH3 mutation in endometrial cancer

Nicholas P Taylor1, Matthew A Powell, Randall K Gibb

  • 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, 4911 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110, USA. taylorni@wustl.edu

Cancer Research
|August 4, 2006
PubMed

Insights

The DNA mismatch repair gene MLH3 may play a role in endometrial cancer. Researchers found inherited variants and somatic mutations in MLH3 in endometrial tumors, suggesting its involvement in cancer development.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • MLH3 is a DNA mismatch repair gene linked to MLH1.
  • Its role in colorectal cancer is debated, prompting investigation into other cancers.

Purpose of the Study:

  • To investigate the role of MLH3 in endometrial tumorigenesis.
  • To analyze tumor and germ line DNA from high-risk endometrial cancer patients.

Main Methods:

  • Analyzed DNA from 57 endometrial cancer patients excluding those with known MSH2, MSH6, or MLH1-methylated tumors.
  • Used single-strand conformational variant analysis to identify MLH3 variants.
  • Performed combined bisulfite restriction analysis for MLH3 promoter methylation.

Main Results:

  • Identified 16 MLH3 variants, including 12 missense changes.
  • Found three somatic MLH3 mutations in 57 tumors.
  • Observed a germ line missense variant with loss of heterozygosity (LOH) in one patient's tumor.
  • No evidence of MLH3 promoter methylation was found.

Conclusions:

  • MLH3 alterations, including inherited variants and somatic mutations, suggest a role in endometrial tumorigenesis.
  • Further research is warranted to clarify MLH3's specific function in endometrial cancer development.